Obermatt
See Similar Stocks →

Flags

Earnings warning

Apellis Pharmaceuticals

NSQ:APLS · US03753U1060
BiotechnologyMedium

360

75
Medium confidence — indicative
Profit price11
Cash yield81
Price/Sales87
EV / Gross Profit81
Price/Book17
Return on Capital94
Cash Return on Capital94
Return on Equity94
EBIT Margin66
Gross Profitability98
Cash Conversion17
Accruals45
Owner Earnings Margin73
Sales growth61
Profit growth61
Reinvestment88
Price momentum14
Debt load12
Refinancing97
Debt Payback36
Liquidity95
Analyst ratings13
Expectations trend75
Market mood19
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Apellis Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePrivate Company
ExchangeNASDAQGS
Founded2009
Employees764
Websiteapellis.com
ISINUS03753U1060
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsHematologyOphthalmologyNeurologyImmunologyNephrologyBiotechnologyHealth CarePharmaceuticalTherapeutics

Description

Apellis Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical company. The company focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibi…

Analysis

Quality compounder

Apellis Pharmaceuticals, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 38.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is mixed and the balance sheet is adequate. The company scores 20/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
87
—
—
—
Price/Earnings
93
—
—
—
Price/Book
17
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
78
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Apellis Pharmaceuticals with its peers
Surrozen
NAQ:SRZN
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Incyte
NSQ:INCY
95
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Kalvista Pharmaceuticals
NMQ:KALV
60
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →